Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Several recent trials indicate low-dose ketamine produces rapid antidepressant effects. However, uncertainty remains in several areas: dose response, consistency across patient groups, effects on suicidality, and possible biases arising from crossover trials. METHODS: A systematic search was conducted for relevant randomized trials in Medline, Embase, and PsycINFO databases up to August 2014. The primary endpoints were change in depression scale scores at days 1, 3 and 7, remission, response, suicidality, safety, and tolerability. Data were independently abstracted by 2 reviewers. Where possible, unpublished data were obtained on treatment effects in the first period of crossover trials. RESULTS: Nine trials were identified, including 201 patients (52% female, mean age 46 years). Six trials assessed low-dose ketamine (0.5 mg/kg i.v.) and 3 tested very low-dose ketamine (one trial assessed 50 mg intra-nasal spray, another assessed 0.1-0.4 mg/kg i.v., and another assessed 0.1-0.5 mg/kg i.v., intramuscular, or s.c.). At day 3, the reduction in depression severity score was less marked in the very low-dose trials (P homogeneity <.05) and among bipolar patients. In analyses excluding the second period of crossover trials, response rates at day 7 were increased with ketamine (relative risk 3.4, 95% CI 1.6-7.1, P=.001), as were remission rates (relative risk 2.6, CI 1.2-5.7, P=.02). The absolute benefits were large, with day 7 remission rates of 24% vs 6% (P=.02). Seven trials provided unpublished data on suicidality item scores, which were reduced on days 1 and 3 (both P<.01) but not day 7. CONCLUSION: Low-dose ketamine appears more effective than very low dose. There is substantial heterogeneity in clinical response, with remission among one-fifth of patients at 1 week but most others having benefits that are less durable. Larger, longer term parallel group trials are needed to determine if efficacy can be extended and to further assess safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ketamine, a glutamatergic agent used routinely for induction and maintenance of anesthesia, exhibits well-replicated, rapid, potent antidepressant effects in randomized controlled trials (i.e., metaanalytic Cohen's d=1.4, a large effect) 12 , even in difficult-to-treat conditions such as treatment-resistant depression 32 and bipolar depression 33 .”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Approach: Intravenous ketamine Evidence: Strong support 12”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As an example, we discuss the potential for ketamine-which exhibits both rapid plasticity-enhancing effects in animal models 4,10 and rapid clinical effects in human patients 11,12 -to provide a test of the predictions of this integrative model, including simultaneous and correlated reversals of multiple plasticity-related deficits across levels of analysis.”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [12]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Larkin, G. L., & Beautrais, A. L. (2011) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000629 · Cited by 258 · cited 2×
“…or even enhanced by repeated dosing, such as the 2 to 3 times weekly schedule that has been assessed in some case series with promising findings (Price et al., 2009; aan het Rot et al., 2010; DiazGranados et al., 2010b; Larkin and Beautrais, 2011; Rasmussen et al., 2013; Shiroma et al., 2014).”
BackgroundRetractedHamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 4×
“The primary endpoint was change in depression severity scores from baseline on depression scales such as the Hamilton Depression Rating Scale (HAM-D; Hamilton, 1960) and/or the Montgomery Åsberg Depression Rating Scale [MADRS]) at the following times: day 1 (24 hours after first dose), day 3, and day 7.”
MethodInfluentialCochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048 · cited 3×
“The I2 statistic was used to assess heterogeneity of trial results, and subgroup heterogeneity was tested using a chi-squared statistic (Higgins and Green, 2009).”
MethodA new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090 · cited 3×
“Diverse measures were used to test possible psychotomimetic, dissociative, or mood elevation symptoms, including Visual Analogue Scale score for intoxication “high” (Aitken, 1969), Brief Psychiatric Rating Scale (Overall and Gorham, 1962), Young Mania Rating Scale (Young et al., 1978), and Clinician Administered Disso…”
MethodA Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 3×
“Diverse measures were used to test possible psychotomimetic, dissociative, or mood elevation symptoms, including Visual Analogue Scale score for intoxication “high” (Aitken, 1969), Brief Psychiatric Rating Scale (Overall and Gorham, 1962), Young Mania Rating Scale (Young et al., 1978), and Clinician Administered Disso…”
MethodMolecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 8×
“The results showed that Visual Analogue Scale score for intoxication “high” scores returned to baseline within 110 minutes of the infusion (Berman et al., 2000).”
BackgroundMethodResultInfluentialA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 1×
“Several additional strands of evidence indicate that the benefit observed in these trials is a result of depression treatment, rather than nonspecific mood elevation or a ‘high’ following ketamine administration: there is improvement in core depressive symptoms such as sadness, suicidality, and helplessness; the time…”
Background
Research works printed but not linked: 2
- Aitken, 1969, Measurement of feelings using visual analogue scales, Proc R Soc Med, 62, 989
- RevMan (2014) The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Cited by
Items 101–200 of 226
Bayes, A. J., Short, B., Zarate, C. A., Park, L., Murrough, J. W., McLoughlin, D. M., Riva‐Posse, P., Schoevers, R. A., Veraart, J. K. E., Parikh, S. V., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.04.020 · Cited by 22
Self-citationKetamine in the Treatment of Depressive Episodes
Ritter, P. S., Findeis, H., & Bauer, M. (2019) · Pharmacopsychiatry · doi:10.1055/a-0991-0582 · Cited by 28
Núñez, N. A., Joseph, B., Kumar, R., Douka, I., Miola, A., Prokop, L. J., Mickey, B. J., & Singh, B. (2023) · Brain Sciences · doi:10.3390/brainsci13121672 · Cited by 23
“This reported dose has been shown to be more effective in reducing depressive symptoms according to a meta-analysis of six trials when compared to lower dosages [37].”
ResultThe science of psychedelic medicine
Siegel, J. S., Liston, C. M., Nicol, G. E., Carhart-Harris, R. L., & Bogenschutz, M. P. (2026) · Nature Medicine · doi:10.1038/s41591-025-04194-5 · Cited by 28
“Some studies have found an association between the two 201 , others have reported that ketamine can remain effective at a dose with minimal dissociative effects 202–204 or with ‘safeners’ that reduce these effects 205,206 .”
Increased use of ketamine for the treatment of depression: Benefits and concerns
Na, K., & Kim, Y. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110060 · Cited by 26
Rygvold, T. W., Hatlestad‐Hall, C., Elvsåshagen, T., Moberget, T., & Andersson, S. (2022) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2022.867675 · Cited by 26
Dai, D., Miller, C., Valdivia, V., Boyle, B. W., Bolton, P., Li, S., Seiner, S. J., & Meisner, R. C. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03789-3 · Cited by 27
Castle, C., Gray, A. R., Neehoff, S., & Glue, P. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725685 · Cited by 22
“, 2000) has been confirmed in multiple subsequent studies (Xu et al., 2016).”
BackgroundResultSelf-citationAsleep DBS under ketamine sedation: Proof of concept
Erdman, H. B., Kornilov, E., Kahana, E., Zarchi, O., Reiner, J., Faust‐Socher, A., Strauss, I., Firman, S., Israel, Z. H., Bergman, H., et al. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105747 · Cited by 21
Sorel, M., Zrek, N., Locko, B., Armessen, C., Ayache, S. S., & Lefaucheur, J. (2018) · Clinical Neurophysiology · doi:10.1016/j.clinph.2018.02.124 · Cited by 20
Expert Opinion on Psychedelic-Assisted Psychotherapy for People with Psychotic SymptomsPreprint
Torre, J. T. L., Mahammadli, M., Greenway, K. T., & Williams, M. T. (2022) · Research Square · doi:10.21203/rs.3.rs-1241397/v1 · Cited by 18
Sayed, A. E. H., Hamed, M., Soliman, H. A. M., & Authman, M. M. N. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-16518-2 · Cited by 17
Pan, Y., Gorenflo, M. P., Davis, P. B., Kaelber, D. C., Luca, S. M. D., & Xu, R. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03033-4 · Cited by 25
Liu, H., Lan, X., Wang, C., Zhang, F., Fu, L., Li, W., Ye, Y., Hu, Z., Chao, Z., Ning, Y., et al. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04388-y · Cited by 18
Xiong, Z., Zhang, K., Ishima, T., Ren, Q., Ma, M., Pu, Y., Chang, L., Chen, J., & Hashimoto, K. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.11.010 · Cited by 17
“Multiple meta-analyses have demonstrated that the N-methyl-D-aspartate receptor (NMDAR) antagonist (R,S)-ketamine exhibits rapid antidepressant and anti-suicidal ideation effects in treatment-resistant patients with major depressive disorder or bipolar disorder (Kishimoto et al., 2016; Newport et al., 2015; Wilkinson…”
Aepfelbacher, J., Panny, B., & Price, R. B. (2024) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2024.100316 · Cited by 18
Anderson, I. M., Blamire, A. M., Branton, T., Brigadoi, S., Clark, R. A., Downey, D., Dunn, G., Easton, A., Elliott, R., Elwell, C. E., et al. (2017) · Efficacy and Mechanism Evaluation · doi:10.3310/eme04020 · Cited by 18
Self-citationWłodarczyk, A., Cubała, W. J., Szarmach, J., Małyszko, A., & Wiglusz, M. S. (2019) · PubMed · Cited by 19
Glutamate-Based Drug Discovery for Novel Antidepressants
Pałucha-Poniewiera, A., & Pilc, A. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1213234 · Cited by 17
Parikh, S. V., Voort, J. L. V., Yocum, A. K., Achtyes, E. D., Goes, F. S., Nykamp, L. J., Singh, B., Lopez-Vives, D., Sera, C. E., Maixner, D. F., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.12.033 · Cited by 16
Faccio, A. T., Rupérez, F. J., Singh, N., Angulo, S., Tavares, M. F. M., Bernier, M., Barbas, C., & Wainer, I. W. (2018) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2018.03.008 · Cited by 14
CYP 450 enzymes influence (R,S)-ketamine brain delivery and its antidepressant activity
Nguyen, T. M. L., McGowan, J. C., & Gardier, A. M. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108936 · Cited by 17
Feifel, D. (2016) · Drug Development Research · doi:10.1002/ddr.21347 · Cited by 17
Assessment of the rapid and sustained antidepressant-like effects of dextromethorphan in mice
Saavedra, J. S., Garrett, P. I., Honeycutt, S. C., Peterson, A. M., White, J., & Hillhouse, T. M. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.173003 · Cited by 15
Truppman Lattie, D., Nehoff, H., Neehoff, S., Gray, A., & Glue, P. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120953991 · Cited by 13
“In addition to its well-documented acute antidepressant effects in treatment-resistant depression (Xu et al., 2016), ketamine also has significant anxiolytic effects.”
BackgroundSelf-citationThe Efficacy and Safety of Concomitant Psychotropic Medication and Electroconvulsive Therapy (ECT)
Janjua, A., Dhingra, A., Greenberg, R., & McDonald, W. (2020) · CNS Drugs · doi:10.1007/s40263-020-00729-1 · Cited by 12
Ketamine for suicidality: An umbrella review
Shamabadi, A., Ahmadzade, A., & Hasanzadeh, A. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15360 · Cited by 14
NMDA Antagonists for Treatment-Resistant Depression
Farber, N. B. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_165 · Cited by 15
Ismail, R. F., Hamed, M., & Sayed, A. E. H. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1237159 · Cited by 15
Efficacy of ketamine for comorbid depression and acute or chronic pain: A systematic review
Balachandran, A., Tassone, V. K., Adamsahib, F., Passa, A.-M. D., Kuburi, S., Demchenko, I., Ladha, K. S., & Bhat, V. (2022) · Frontiers in Pain Research · doi:10.3389/fpain.2022.1022767 · Cited by 17
Systemic neuro-dysregulation in depression: Evidence from genome-wide association
Tubbs, J. D., Ding, J., Baum, L., & Sham, P. C. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.08.007 · Cited by 12
Ketamine treatment for depression: A model of care
Bayes, A. J., Dong, V., Martin, D. M., Alonzo, A., Kabourakis, M., & Loo, C. K. A. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674211039166 · Cited by 12
“Those with severe suicidality in the context of MDD may benefit from ketamine treatment, with a rapid reduction in ideation found in this patient group (Xu et al., 2016) with a similar result seen with esketamine (Canuso et al.”
BackgroundResultSelf-citationA continuum hypothesis of psychotomimetic rapid antidepressants
Haarsma, J., Harmer, C. J., & Tamm, S. (2021) · Brain and Neuroscience Advances · doi:10.1177/23982128211007772 · Cited by 13
Echegaray, M. V. F., Mello, R. P., Magnavita, G. M., Leal, G. C.-G., Correia‐Melo, F. S., Jesus‐Nunes, A. P., Vieira, F., Bandeira, I. D., Caliman‐Fontes, A. T., Telles, M., et al. (2023) · Trends in Psychiatry and Psychotherapy · doi:10.47626/2237-6089-2022-0593 · Cited by 14
“38,39 However, the correlation between blood ketamine/esketamine levels and therapeutic efficacy may be encompassed within a therapeutic window for ketamine/esketamine that has not been defined yet.”
Li, X., Shi, Z.-M., Wang, P., & Hu, H. (2020) · General Psychiatry · doi:10.1136/gpsych-2019-100117 · Cited by 12
Chen, C., Pang, Q., Tu, A., Wang, J., & Tu, F. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13263 · Cited by 12
Ramírez-Paesano, C. R., Galceran, A. J., Clarens, C. R., García, V. G., Abadal, B. O., Cobo, V. V., Nebot, B. R., González, S. J., López, L. C., Santaliestra, J., et al. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01795-4 · Cited by 12
Sohn, M. N., Cole, J., Bray, S., & McGirr, A. (2025) · Psychological Medicine · doi:10.1017/s0033291724003313 · Cited by 11
“For example, subanesthetic ketamine rapidly reduces suicidal ideation for up to 72 h (Witt et al., 2020; Xu et al., 2016), an effect that may be maintained using high doses of D-cycloserine (Chen et al., 2019).”
Self-citationHussain, S., Gale, C. K., Sarma, S., Smith, J. P., Bayes, A. J., & Loo, C. K. A. (2025) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674251333577 · Cited by 11
“Ketamine has advantages to standard antidepressants in terms of speed of onset, with potential reduction of symptoms within 6–12 hours after a single dose, though this effect generally lasts less than a week (Bayes et al., 2021; Malhi et al., 2021; Nikolin et al., 2023; Xu et al., 2016).”
Self-citationClinical and behavior characteristics of individuals who used ketamine
Lee, T. S., Liu, Y.-H., Huang, Y.-J., Tang, W. K., Wang, Y., Hu, S., Lin, C., Li, C. R., & Hung, C. (2022) · Scientific Reports · doi:10.1038/s41598-022-04832-9 · Cited by 12
Song-Smith, C., Jacobs, E., Rucker, J., Saint, M., Cooke, J. E., & Schlosser, M. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-083595 · Cited by 12
“15 Clinical investigations into the therapeutic efficacy of related drugs, such as 3,4-methylenedioxymethamphetamine (MDMA) for post-traumatic stress disorder (PTSD) 16 17 and ketamine for depression, 18–20 have also advanced substantially.”
BackgroundO’Brien, B., Green, C. E., Jurdi, R. K. A., Chang, L. C., Lijffijt, M., Iqbal, S., Iqbal, T., Swann, A. C., & Mathew, S. J. (2019) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2019.100432 · Cited by 13
The Role of Gut Microbiota in the Antidepressant Effects of Ketamine
Wang, Y., Xu, X., Luo, A., & Yang, C. (2020) · Springer eBooks · doi:10.1007/978-981-15-2902-3_8 · Cited by 10
Bottemanne, H., Claret, A., & Fossati, P. (2020) · L Encéphale · doi:10.1016/j.encep.2020.08.006 · Cited by 15
Elwyn, R., Mitchell, J., Kohn, M. R., Driver, C., Hay, P., Lagopoulos, J., & Hermens, D. F. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105122 · Cited by 11
Earleywine, M., Altman, B. R., & De Leo, J. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2021.1912863 · Cited by 9
“resistant depression (Cipriani et al. 2018; McGirr et al. 2015; Xu et al. 2016), and those who have used at least two medications with little improvement might respond to more detailed descriptions or individualized discus-”
BackgroundÖzgen, M. H., & van den Brink, W. (2022) · Psychiatry and Clinical Psychopharmacology · doi:10.5152/pcp.2022.22037 · Cited by 10
“32-34 We hope that the increase in knowledge about the value of psychedelics in the treatment of psychiatric patients will be accompanied by explicit guidelines about their application and by proper regulation of psychedelic treatment practice with guarantees for the quality and safety of the…”
BackgroundThe practicalities and ethics of ketamine for depression
Ryan, C. J., & Loo, C. K. A. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30155-4 · Cited by 9
Self-citationPortal, B., Södergren, M., Borrell, T. P. I., Giraud, R., Metzendorf, N. G., Hultqvist, G., Nilsson, P., & Lindskog, M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231461 · Cited by 10
Cognitive inflexibility, obsessive-compulsive symptoms and traits and poor post-pandemic adjustment
Frota Lisboa Pereira de Souza, A. M., Pellegrini, L., & Fineberg, N. A. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.104073 · Cited by 8
“…pharmacological agents on cognitive flexibility in humans, including SSRI (Brig-man et al., 2010), levodopa (Cools et al., 2003), memantine (Grant et al., 2010), ketamine (Murrough et al., 2013; Price and Duman, 2020; Xu et al., 2015) and psilocybin (de Veen et al., 2017; Rodan et al., 2021).”
Carboni, L., Nguyen, T., & Caberlotto, L. (2016) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201500149 · Cited by 8
“In line with the hypothesis that glutamatergic signalling is involved in the molecular underpinnings of MDD, recent clinical findings have demonstrated that ketamine, an NMDA glutamate receptor antagonist, is able to induce a rapid and long –lasting antidepressant response in patients suffering from severe depression…”
ResultSuccessful use of ketamine to treat severe depression with suicidality post-COVID-19 – A case report
Meha, S., Suhas, S., & Rao, N. P. (2022) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2022.100100 · Cited by 6
“5mg/kg of ketamine over 40 minutes at the rate of 75ml/hr as per the previous study protocols (Xu et al., 2016).”
MethodEshkevari, L., Sales, M. A. M., Collins, C., Totoraitis, J., Donohue, L., Dalley, C. B., Bregman, B., Negro, P., Gordon, S., & Estrada, C. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115949 · Cited by 8
Ketamine nano-delivery based on poly-lactic-co-glycolic acid (PLGA) nanoparticles
Hirano, S., Bovi, M., Romeo, A., Guzzo, F., Chiamulera, C., & Perduca, M. (2018) · Applied Nanoscience · doi:10.1007/s13204-018-0765-1 · Cited by 6
The Effect of Propofol on a Forced Swim Test in Mice at 24 Hours
Daniel, D. G., Daniel, D. T., Daniel, D. T., Flynn, L. C., & Allen, M. H. (2020) · Current Therapeutic Research · doi:10.1016/j.curtheres.2020.100590 · Cited by 6
Lee, W., Sheehan, C., Chye, R., Chang, S., Loo, C. K. A., Draper, B., Agar, M. R., & Currow, D. C. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-052312 · Cited by 8
Self-citationZhu, Y., Feng, W., Kong, Q., Sheng, F., Li, Z., Xu, W., Li, Q., Han, Y., Wu, X., Jia, C., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1298661 · Cited by 10
Stocker, K., Hartmann, M., Reissmann, S., Kist, A., & Liechti, M. E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.916641 · Cited by 7
Ketamine: Clinical Studies in Treatment-Resistant Depressive Disorders
Blier, P., & Blier, J. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0_3 · Cited by 9
Xiao, X., Bentzley, B. S., Cole, E. J., Tischler, C., Stimpson, K. H., Duvio, D., Bishop, J. H., DeSouza, D. D., Schatzberg, A. F., Keller, C. J., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/672154 · Cited by 7
“J Child Psychol Psychiatry 55(12):1317– 1327.”
BackgroundThornton, N. L. R., Wright, D. J., & Glozier, N. (2024) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674241237094 · Cited by 6
“The rapid-acting antidepressant effect of single-dose ketamine often fades within a week and thus, repeat-dosing is deemed necessary to prolong the acute efficacy (Kryst et al., 2020; Xu et al., 2016).”
BackgroundSelf-citationThe quest for optimal ketamine dosing formula in treatment-resistant major depressive disorder
Kwaśna, J., Cubała, W. J., Kwaśny, A., & Wilkowska, A. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00637-x · Cited by 5
“Research indicates that lower doses (0.1– 0.2 mg/kg) of ketamine either lack clear or consistent evidence of clinically meaningful efficacy [ 13, 15] or provide smaller and shorter-lived benefits compared to the 0.5 mg/ kg dose [16, 17].”
InfluentialKetamine for postoperative avoidance of depressive symptoms: the K-PASS feasibility randomised trial
Fritz, B. A., Pennington, B. R. T., Dalton, C., Horan, C., Palanca, B. J. A., Schweiger, J. A., Griffin, L., Tumwesige, W., Willie, J. T., & Farber, N. B. (2023) · BJA Open · doi:10.1016/j.bjao.2023.100245 · Cited by 5
Ketamine and Electroconvulsive Therapy
Loo, C. K. A., & Gálvez, V. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0_8 · Cited by 5
Self-citationThe effects of low dose MK-801 administration on NMDAR dependent executive functions in pigeons
Gökhan, N., Neuwirth, L. S., & Meehan, E. F. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.02.009 · Cited by 7
Praktische Aspekte der Ketaminbehandlung – Sicherheit, Kombinationstherapien und Komorbiditäten
Findeis, H., Ludwig, V. M., Mikoláš, P., Graff, J., Bauer, M., & Ritter, P. S. (2022) · Der Nervenarzt · doi:10.1007/s00115-021-01260-4 · Cited by 5
The Use of Intravenous Lidocaine as an Analgesic Modality in the Austere Environment: Two Cases
Dryden, B., Kerr, W. B., Higgins, S., Tou, K., & Dhanjal, S. T. (2022) · Wilderness and Environmental Medicine · doi:10.1016/j.wem.2022.04.010 · Cited by 5
“9 The risk of local anesthetic systemic toxicity, a constellation of mainly cardiovascular and neurologic side effects, is typically seen when serum lidocaine concentrations exceed 5 to 10 mcg · mL -1 .”
BackgroundHjorth, S. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116647621 · Cited by 7
Infusing Hope Into the Treatment of Suicidality: a Review of Ketamine’s Effects on Suicidality
Rengasamy, M. L., Hsiung, K. S., & Price, R. B. (2019) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-019-00184-3 · Cited by 5
Valizadeh, A., Roache, J. D., Zhang, X., Hu, Y., Gueorguieva, R. V., Averill, L. A., Ranganathan, M., Wang, Z., Williamson, D. E., Shiroma, P. R., et al. (2025) · iScience · doi:10.1016/j.isci.2025.114445 · Cited by 3
Courtes, A. C., Jones, G. H., Henter, I. D., Shahani, L., Fries, G. R., Juruena, M. F., Soares, J. C., Zarate, C. A., & Machado‐Vieira, R. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120016 · Cited by 5
Horáček, J., Janda, R., Görnerová, N., Jajcay, L., & Andrashko, V. (2023) · Neuroscience Letters · doi:10.1016/j.neulet.2023.137095 · Cited by 5
Finnegan, M., Ryan, K. M., Shanahan, E., Harkin, A., Daly, L., & McLoughlin, D. M. (2016) · Pilot and Feasibility Studies · doi:10.1186/s40814-016-0080-0 · Cited by 5
“These effects are mediated, at least in part, via Akt/GSK-3/mammalian target of rapamycin (mTOR) signalling and increased dendritic translation of synaptic proteins [16], as well as deactivation of eukaryotic elongation factor 2 (eEF2) kinase, resulting in de-suppression of brain-derived neurotrophic factor (BDNF) tra…”
BackgroundChen, J. C. C., Sumner, R. L., Naga, V. K., Hoeh, N. R., Ayeni, H. A., Singh, V., Sundram, F., Campbell, D., & Muthukumaraswamy, S. D. (2020) · Trials · doi:10.1186/s13063-020-4089-6 · Cited by 4
Bahji, A., Vázquez, G. H., & Zarate, C. A. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.12.069 · Cited by 5
“While perfect congruence across trials cannot exist given the lack of standardization, several statistical methods fortunately allow researchers to manage deviations from the ideal scenario (Dold et al., 2020; McIntyre et al., 2020; Nelson and Papakostas, 2009; Witt et al., 2020; Xu et al., 2016).”
BackgroundXu, R., Pan, Y., Gorenflo, M. P., Davis, P. B., Kaelber, D. C., & Luca, S. M. D. (2023) · Research Square · doi:10.21203/rs.3.rs-3207199/v1 · Cited by 4
Correlations between major depressive disorder, splenic morphology, and immune function
Lin, Z., Xu, X., Zhang, K., Wang, T., Cao, L., Wang, Z., & Wang, G. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06853-w · Cited by 5
“A slow infusion of ketamine (0.5 mg/kg over 40 min) significantly reduces depressive symptoms lasting about one week [28].”
InfluentialIntegrative Interventions for Improving Outcomes in Depression: A Narrative Review
Halma, M. T. J., Plothe, C., & Marik, P. E. (2024) · Psychology International · doi:10.3390/psycholint6020033 · Cited by 2
Selinger, M. C., Compton, D. M., Morris, H., & Canty, T. J. (2023) · Journal of Behavioral and Brain Science · doi:10.4236/jbbs.2023.1312016 · Cited by 5
Ketamine Infusion (KI) in Treatment Resistant Depression (TRD): Retrospective Clinical Data Analysis
Griffiths, C., O’Neill-Kerr, A., Vai, R. D., Sore, T., & da Silva, K. M. (2019) · Open Journal of Depression · doi:10.4236/ojd.2019.83007 · Cited by 4
“The results may link to evidence indicating that a subanaesthetic ketamine treatment dose provides a rapid and effective, but short term, antidepressant action (Coyle & Laws, 2015; Fond et al., 2014; Grady et al., 2017; Kishimoto et al., 2016; Xu et al., 2015).”
BackgroundInfluentialNarzissmus, Trauma und Depression: Klinische Beobachtungen aus der MODE-Studie
Leuzinger‐Bohleber, M. (2024) · PTT - Persönlichkeitsstörungen: Theorie und Therapie · doi:10.21706/ptt-28-3-318 · Cited by 4
With great power comes great responsibility: Promise and caution in the new psychedelic renaissance
Halma, M. T. J., Levy, R., & Varón, J. (2025) · Brain Disorders · doi:10.1016/j.dscb.2025.100286 · Cited by 2
Oral Prolonged-Release Ketamine for Treatment-Resistant Depression: Two Randomized Clinical Trials
Walter, M., zu Eulenburg, C., Damyanova, A., Schmid, K., Schwienbacher, I., Papanastasiou, E., Maiboe, K., Arvastson, L., Strote, C., Gehrlach, D., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.19121 · Cited by 4
Genetic signatures of suicide attempt behavior: insights and applications
Drago, A. (2024) · Expert Review of Proteomics · doi:10.1080/14789450.2024.2314143 · Cited by 2
“Ketamine and esketamine are effective in the acute reduction (up to day 7) of suicidal ideation [37,38], but their effect in the long term and is not reported.”
BackgroundThe Role of Ketamine in Treatment-resistant Depression: A Narrative Review
Reddy, A., Patel, S. G., Barik, A. K., Thappa, P., Jangra, K., Kaur, K., Chauhan, R., & Luthra, A. (2024) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2024.00003 · Cited by 4
Racial-Ethnic Disparities in Ketamine and Esketamine Therapy for Major Depressive Disorder
Liu, M., Branning, R., Lee, A., Kaelber, D. C., & Gao, K. (2025) · Psychiatric Services · doi:10.1176/appi.ps.20240559 · Cited by 4
Glue, P., Loo, C. K. A., Rodgers, A., Gálvez, V., Somogyi, A. A., & Mitchell, P. B. (2016) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2016.1181782 · Cited by 2
“For example, the lower rate of adverse effects reported in the trial by Lapidus et al. (2014) is likely accounted for by lower ketamine dosage and blood concentrations (also resulting in lower efficacy; Xu et al. 2016) than by use of the intranasal route of administration.”
BackgroundSelf-citationWang, M., Xiong, Z., Su, B., Wang, L., Li, Z., Yang, Y., Fang, J., & Li, Z. (2019) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13041 · Cited by 5
Overview of ketamine for major depression: efficacy and effectiveness
Bahji, A., Vázquez, G. H., Brietzke, E. M., & Zarate, C. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821033-8.00005-8 · Cited by 2
Recent advances and challenges in major depressive disorder
Kim, Y. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110403 · Cited by 2
Ketamine Usage Effectivity on Treatment-Resistant Depression Diagnosed Patients: a Scoping Review
Nugroho, S. W., Konginan, A., Sari, G. M., & Yulianti, E. (2024) · Jurnal Psikiatri Surabaya · doi:10.20473/jps.v13i1.34068 · Cited by 1
Lee, Y.-C., Zhao, E., Lee, K. K. H., Lee, W., Dumitrescu, A., Loadsman, J. A., Sanders, R., Brake, T., & Wang, A. Y.-Y. (2025) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360288.2025.2531008 · Cited by 1
“There is also accumulating evidence of its benefit in the treatment of major depression and mood disorders (21).”
Choi, W.-S., Woo, Y. S., Bahk, W., Kim, N.-Y., Park, S., Kim, W., Lee, J. G., Yang, C.-M., Sung, H. M., Wang, S., et al. (2025) · 신경정신의학 · doi:10.4306/jknpa.2025.64.3.178 · Cited by 1
Novel treatment possibilities in depression and schizophrenia
Češková, E. (2018) · Psychiatrie pro praxi · doi:10.36290/psy.2018.013 · Cited by 1
Should Ketamine Not Be Banned? A Scoping Review
Usman, M. A. (2021) · Disaster Medicine and Public Health Preparedness · doi:10.1017/dmp.2021.292 · Cited by 4
“…Bias Performance Bias Mion et al. 2017 Retrospective Cohort ✓ Jones et al. 2018 Systematic Review ✓ Slomski et al. 2019 RCT ✓ Dakwar et al. 2020 RCT Xu et al. 2016 Systematic Review/Meta-Analysis Yan et al. 2020 Narrative Review Farrell et al. 2018 Narrative Review ✓ ✓ Cohen et al. 2015…”
BackgroundBiologisch unterstützte psychotherapeutische Interventionen bei therapieresistenten Depressionen
Richter, J., & Nazarenus, E. (2022) · Springer eBooks · doi:10.1007/978-3-662-65734-8_26 · Cited by 1
A Pain Physician and Anesthesiologist’s Perspective on Ketamine for Treatment-Resistant Depression
Gatewood, L. E., Gorlin, A. W., Bailey, C. H., Barsoum, G., & Porter, S. B. (2023) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-023-01439-7 · Cited by 1
“Patients with bipolar depression, rather than unipolar depression, were more resistant to ketamine’s beneficial effects [51].”
Schwartz, O., Amminger, G. P., Baune, B., Bedi, G., Berk, M., Cotton, S., Daglas‐Georgiou, R., Glozier, N., Harrison, B. J., Hermens, D. F., et al. (2023) · Trials · doi:10.1186/s13063-023-07631-3 · Cited by 3
“This calculation uses an effect size estimate based on recent meta-analysis for change in depressive symptoms 7 days after a single dose of ketamine [21].”
MethodSelf-citationWoody, M. L., Rohac, R., Cooper, I., Griffo, A., Mcdonald, N., Spotts, C., Fournier, J. C. J., Jones, N. P., Peciña, M., Young, K. D., et al. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.10.024 · Cited by 1
Gabriela Ribeiro, P. E. N. A., Zonzini, F. H. T., & Bonetti, A. D. F. (2024) · Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde · doi:10.30968/rbfhss.2024.154.1122
“Dentre aqueles que apresentaram efeitos adversos leves 18,27,28,32,33 , um estudo reportou diminuição desses eventos em até 80 minutos 17 , e outro descreveu 14 efeitos adversos distintos, mas sem gravidade maior, tais como ansiedade, visão turva, dissociação, tontura, dor de cabeça, diminuição do…”
Metadata
- Authors
- Xu, Y., Hackett, M., Carter, G., Loo, C., Gálvez, V., Glozier, N., Glue, P., Lapidus, K., McGirr, A., Somogyi, A. A., Mitchell, P. B., & Rodgers, A.
- Affiliations
- The University of Sydney (AU)
- Corresponding author
- Loo, Colleen
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-11-17
- Volume
- 19
- Issue
- 4
- Pages
- pyv124
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC4851268
- OpenAlex
- W2197394318
- Cited by
- 226
- References
- 44
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 22 · 2023: 22 · 2022: 22 · 2021: 20 · 2020: 29 · 2019: 26 · 2018: 28 · 2017: 24 · 2016: 13
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- UNSWorks (UNSW Sydney) (submittedVersion, cc-by-nc-nd)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by)
- Figshare (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, other-oa)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- National Institute of Mental Health (K23MH104465)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- ketamine, major depressive disorder, low-dose ketamine, rapid antidepressant effects, dose-response relationship, remission, response rate, suicidality, bipolar disorder, crossover trial, safety and tolerability
- MeSH terms
- Antidepressive Agents, Major Depressive Disorder, Humans, Ketamine, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.